NASDAQ:XNCRXencor Stock Price, Forecast & News

Xencor's stock was trading at $28.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XNCR stock has increased by 14.3% and is now trading at $32.14.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 2 sell ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Xencor.

Xencor is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Xencor.

Xencor Inc (NASDAQ:XNCR) posted its earnings results on Tuesday, August, 4th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.05. Xencor had a negative net margin of 113.40% and a negative return on equity of 13.56%.
View Xencor's earnings history.

8 equities research analysts have issued 1-year price objectives for Xencor's stock. Their forecasts range from $21.00 to $52.00. On average, they anticipate Xencor's stock price to reach $41.00 in the next year. This suggests a possible upside of 27.6% from the stock's current price.
View analysts' price targets for Xencor.

News stories about XNCR stock have been trending negative this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xencor earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Xencor.

Some companies that are related to Xencor include Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), Schrodinger (SDGR), HUTCHISON CHINA/S (HCM), Allakos (ALLK) and Legend Biotech (LEGN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Cypress Semiconductor (CY), Apollo Global Management (APO), Intel (INTC), AbbVie (ABBV), Exelixis (EXEL), Fossil Group (FOSL), NVIDIA (NVDA) and Abercrombie & Fitch (ANF).

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Xencor's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.81%), Principal Financial Group Inc. (0.69%), Rhenman & Partners Asset Management AB (0.46%), WINTON GROUP Ltd (0.32%), Swiss National Bank (0.20%) and Mutual of America Capital Management LLC (0.15%). Company insiders that own Xencor stock include Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III, Paul A Foster and Ronin Capital, Llc.
View institutional ownership trends for Xencor.

XNCR stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Rhenman & Partners Asset Management AB, WINTON GROUP Ltd, Mutual of America Capital Management LLC, Smith Asset Management Group LP, Texas Permanent School Fund, PNC Financial Services Group Inc., and Arizona State Retirement System. Company insiders that have sold Xencor company stock in the last year include John J Kuch, John R Desjarlais, John S Stafford III, and Ronin Capital, Llc.
View insider buying and selling activity for Xencor.

XNCR stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., First Trust Advisors LP, Russell Investments Group Ltd., Rafferty Asset Management LLC, Swiss National Bank, Mackay Shields LLC, Diversified Trust Co, and Principal Financial Group Inc..
View insider buying and selling activity for Xencor.

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XNCR stock can currently be purchased for approximately $32.14.

Xencor has a market capitalization of $1.84 billion and generates $156.70 million in revenue each year. The biopharmaceutical company earns $26.88 million in net income (profit) each year or $0.46 on an earnings per share basis. Xencor employs 156 workers across the globe.

The official website for Xencor is www.xencor.com.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]